Journal article
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
J Cortes, HS Rugo, DW Cescon, SA Im, MM Yusof, C Gallardo, O Lipatov, CH Barrios, J Perez-Garcia, H Iwata, N Masuda, MT Otero, E Gokmen, S Loi, Z Guo, X Zhou, V Karantza, W Pan, P Schmid
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2022
Abstract
BACKGROUND In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS; the number of PD-L1-staining tumor cells, lymphocytes, and macrophages, divided by the total number of viable tumor cells, multiplied by 100) of 10 or more. The results of the final analysis of overall survival have not been reported. METHODS We randomly assigned patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in ..
View full abstractGrants
Funding Acknowledgements
Supported by Merck Sharp and Dohme.